Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/nephrology.1.003
The Role of Direct Oral Anticoagulants in Advanced Chronic Kidney Disease – Questions and Future directions
Filip Ionescu1, Saima Mansuri2,*
- 1Department of Internal Medicine, Beaumont Health System, Royal Oak, OUWB School of Medicine, Royal Oak, MI, USA
- 2Department of Nephrology, Beaumont Health System, Royal Oak, OUWB School of Medicine, Royal Oak, MI, USA
Corresponding Author
Mansuri Saima, Saima.mansuri@beaumont.org
Received Date: July 12, 2021
Accepted Date: July 28, 2021
Ionescu F, Mansuri S. The Role of Direct Oral Anticoagulants in Advanced Chronic Kidney Disease – Questions and Future directions. Arch Nephrol Ren Stud. 2021;1(1):16-20.
Copyright: © 2021 Ionescu F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
The Role of Direct Oral Anticoagulants in Advanced Chronic Kidney Disease – Questions and Future directions
With the advent of the direct oral anticoagulants (DOACs), patients requiring anticoagulation for common conditions such as atrial fibrillation and venous thromboembolism no longer need to worry about dietary restrictions or regular monitoring of the international normalized ratio which complicated warfarin treatment.
CD146-Positive Tumors are Associated with Venous Thromboembolism
The role of CD146 and its soluble form have been intensely reviewed in the processes of cancer and inflammation. However, how CD146 is linked to coagulation and thrombotic events remains unclear. The aim of this paper is to shed light on this topic and clarify the contribution of CD146 as a procoagulant factor.
Aldosterone Synthase Inhibitors for Treatment of Hypertension and Chronic Kidney Disease
Aldosterone excess is known to worsen hypertension and kidney function. Three selective aldosterone synthase inhibitors (ASIs) were evaluated in 3 phase 2 trials. In the first study, the ASI baxdrostat 2 mg orally once daily decreased systolic blood pressure (SBP) by 11.0 mmHg compared with placebo after 12 weeks in patients with treatment-resistant hypertension. In the second study including patients with uncontrolled hypertension, placebo-corrected reduction in SBP with lorundrostat 50 mg once daily was 9.6 mmHg after 8 weeks.